Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6

Benzinga Newsdesk www.benzinga.com Neutral 59.2%

Neg 0% Neu 59.2% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.